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Abstract
A growing body of work is investigating the safety and efficacy of light in Parkinson’s disease 
(PD). Here we discuss the potential of this emerging therapy to improve both motor and non-
motor symptoms of PD. We also highlight directions for future basic, translational and clinical 
research that is critical for the development of mechanism-based protocols of light therapy in PD.
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Main text
Parkinson’s disease and the rational of light therapy
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder. PD is 
diagnosed primarily by progressive and age-dependent deterioration of motor functions (i.e. 
bradykinesia, resting tremor, muscular rigidity and postural instability) [1]. Despite the 
primacy of this motor dysfunction in the clinical diagnosis of PD, patients with PD display 
also a wide range of non-motor symptoms (NMS) including sleep disturbances, cognitive 
deficits, sensory impairments, as well as psychiatric problems such as depression, anxiety 
and psychosis [1]. In fact. at advanced stage of the disease, NMS tend to dominate the 
clinical picture of PD and become the main determinants of the overall quality of life of PD 
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patients and decisions on their institutionalization [1]. Currently, therapies that effectively 
target NMS are lacking, and are therefore the second key unmet clinical need in addition to 
disease-modifying treatments [1]. These challenges are in stark contrast to the highly 
efficacious therapies currently available for motor aspects of the disease [1]. In view of this, 
growing interest is currently underway in the development of alternative treatment 
modalities for PD. Light therapy is one of these novel therapies [2–6]. The rationale of 
introducing light therapy to PD clinic resides in the well-documented therapeutic effect of 
bright light in other neurological and neuropsychiatric disorders [7], some of which co-exist 
in PD patients [1]. Here, we briefly summarise the results of the early studies that assessed 
the efficacy and safety of light therapy in PD, and discuss caveats, which future clinical and 
fundamental research efforts need to address. We also highlight the potential of these 
fundamental insights in helping the development of more efficacious and mechanism-based 
protocols of light therapy in PD.
Therapeutic effects of light in PD
As a salient alternating environmental cue, light acts as one of the most powerful signal that 
influences our behaviour and health [7]. As such, over the last three decades, exposure to 
bright light has been used as a therapy to treat several disorders including mood disorders, 
cognitive disabilities, circadian misalignment, and alterations of sleep/wake behaviour [7]. 
Building on this experience, bright light therapy (BLT) has been recently introduced to PD 
with the perspective of improving the quality of life of PD patients. So far only four studies 
have assessed the efficacy and safety of BLT in PD patients [2–5]. Bright light pulses of 
intensities and durations ranging from 1.000 to 10.000 lux and 30min to 1.5h respectively 
were used daily either in the morning (1h after awakening [3]) or in the evening (1h before 
bedtime [2,4]) or twice daily [5] over varying periods, from one week to several months [2–
5]. Efficacy of BLT was assessed using both routine clinical examination of PD patients over 
time and several validated instruments and questionnaires that evaluate both motor and NMS 
in PD patients. Taken together, these studies have demonstrated that BLT significantly 
improves motor dysfunction including bradykinesia, rigidity, tremor, nocturnal movements, 
dyskinesia and postural imbalance [2–4]. Improvements in motor functions were also 
captured with actigraphy, an objective measurement of overall physical activity in the most 
recent study [5]. Like in other forms of depression [7], bright light had anti-depressant and 
anti-anxious effects in PD patients. Several alterations of sleep behaviour were improved. 
These included insomnia, excessive daytime sleepiness and the overall fragmentation of 
sleep/wake cycle [3–5]. The rate of improvement of these symptoms was variable; both 
anxiety and insomnia improved quickly within days while motor functions improved slowly 
over months to years [2–5]. Near-infrared light (NIr; 670nm) therapy has also been tested in 
the context of PD. Although still in its pre-clinical stage, when applied intracranially just 
above the midbrain, NIr light reduced clinical signs and offered neuroprotections against 
MPTP intoxication in a non-human primate model of PD [13]. In summary, these results 
suggest that light has a substantial therapeutic potential for both motor and NMS of PD. 
However, the field is still in its infancy and further investigations are needed. For example, in 
many ways, current understanding of both the mechanisms of light therapy and PD 
pathology are not incorporated in the design of light therapy protocols. In the next section, 
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we highlight these shortcomings and provide directions for future research that might 
improve the benefits that light therapy may have for the PD population.
Towards mechanism-based bright light therapy for PD
Since light exerts its effects primarily through the eyes, the efficacy of BLT will depend on 
the functional capacity of eyes. The non-visual effects of light are mediated by intrinsically 
photosensitive melanopsin-containing retinal ganglia cells (mRGCs) [8]. Although 
constituting a small subset (1–2%) of visual retinal ganglion cells, these cells are at the 
origin of the retinohypothalamic tract through which they project to several subcortical areas 
[8]. Several studies have described retinal neuropathology in PD including dopamine 
depletion and neurodegeneration affecting RGCs and optic nerves [9]. However, whether 
mRGCs are affected in PD is currently unknown. Interestingly, a recent study using 
chemogenetic activation of mRGCs in dark-housed mice, which simulates the excitatory 
effects of bright light, has indicated that the non-visual effects of light are selectively 
mediated by mRGCs [8]. Circadian phase resetting, mood and vigilance state modulation are 
among these light modulated physiological effects [8,9]. In line with the anatomy of 
mRGCs, the study also showed that mRGCs mediate the activation of several brain 
structures involved in the regulation of widespread aspects of physiology and behaviour that 
are dysfunctional in PD [8]. Elucidation of the anatomical and functional integrity of 
mRGCs in PD will facilitate our understanding of the afferent pathways of light signalling in 
PD. Furthermore, full examination of the temporal dimension — and the extend — of 
dysfunction of the different projections of mRGCs over disease progression will be crucial 
in adjusting light parameters over time to maintain maximum therapeutic benefit.
The efficacy of LT depends also on the timing, intensity, duration and wavelength of the 
received light [7]. They collectively represent “the dose” of LT that should be appropriately 
prescribed to patients. For PD patients, the optimal values for each of these dosing 
parameters is unknown. Studies conducted so far used intensities from 1.000 to 10.000 lux 
and durations of 30min to 1.5h. Only polychromatic white light was used and the timing of 
administration was not based on the chronotype of patients [2–5]. This last point is pertinent 
given that one mechanism by which light exerts its therapeutic effect is by reinforcing 
circadian patterning of the internal physiology and its appropriate entrainment to the external 
world [7]. Alterations of the circadian system and their heterogeneity in PD patients make 
the calibration of light parameters challenging [9]. Further complicating the matter is poor 
understanding of the pathophysiology of the neuronal circuitry underlying circadian rhythms 
in PD. Such fundamental knowledge is essential in order to design protocols of light therapy 
that should also incorporate mechanistic understanding of PD-specific neurodegeneration. 
To gain such knowledge, future research should take advantage of the rapidly evolving 
technologies that allow temporal and genetically-specific manipulation of neuronal networks 
in animal models of PD as well as in vivo imaging of widespread aberrant neuronal 
networks. In clinical settings, large scale multi-center trials with multiple treatment arms are 
needed.
The synchronization of circadian rhythms is not the only mechanism of LT. In patients 
suffering from seasonal depression, it has been shown that the correlation between the 
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magnitude of circadian consolidation and the anti-depressive effect of light accounts for only 
14% of the variance, suggesting that the main action of LT is mediated by non-circadian 
mechanisms [7]. Currently, the mechanisms of light therapy in PD are unknown. The results 
of an ongoing double-blind clinical trial are expected to shed some light on the relative 
contribution of circadian-mediated vs non-circadian processes to the therapeutic effects of 
light in PD patients [6]. However, two of the four trials conducted so far have shown that PD 
patients receiving supplemental light are able to reduce the amount of L-DOPA to 50% 
while maintaining therapeutic efficacy, compared to a 17% increase in L-DOPA 
requirements in untreated patients [2,4]. These observations suggest that BLT could mediate 
its therapeutic effects by enhancing dopamine (DA) neurotransmission, although more direct 
evidence would be needed to support this possible link. Consistently with this hypothesis, 
electrophysiological studies in rodents showed that DA neurons respond to light [10]. 
Additional research on how light influences DA signalling – including the possibility of 
potential interference with the progressive DA neurodegeneration – will be crucial in 
advising, for instance, on the time (early or late) and the nature (acute or chronic) of 
interventions with light in PD. This possibility is particularly pertinent given the non-
invasive nature of BLT and the emerging strategies used to identify people at high risk of 
developing PD [1,7].
Another potential, yet not systematically studied, mechanism of BLT in PD is the 
neuroplastic remodelling of brain circuits. Neuroplastic changes, defined as adjustment 
through neuronal re-organisation, have been shown in the DA system following chronic 
regimes of exposure to [11] or deprivation from light [12]. In principle, these plastic changes 
could operate in other brain structures including all targets of mRGCs. Future research on 
the impact of light on DA and non-DA circuits in PD holds the promise of extending the 
scope of light therapy to alleviate several NMS of PD such as cognitive dysfunctions.
Concluding remarks
For over 30 years, LT has been used as adjuvant therapy in several medical conditions. In 
addition to its well-established therapeutic effects, this intervention has an unusually benign 
side-effect profile. Given the paucity of efficacious treatments for NMS in PD, the safety and 
therapeutic benefits of BLT is currently investigated in the PD population. Although the 
results of several initial trials are promising, we argue that future trials should leverage 
knowledge about the mechanism of action of light in the context of PD-specific 
neurodegenerative process. At the fundamental level, future research should aim at 
investigating underlying mechanisms of BLT in both PD patients and animal models of PD. 
The implementation of these mechanistic insights in the design of BLT protocols in clinical 
setting is expected to yield better outcomes in improving the quality of life by either 
alleviating symptoms or perhaps by modulating the disease biology and slowing down 
disease progression.
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